Rheumatologie und Hepatologie interdisziplinär

Zusammenfassung

Rheumatologische und hepatologische Erkrankungen haben einige Überschneidungen, die für Behandler aus beiden Disziplinen relevant sind. In dieser Übersicht wird ein Schlaglicht auf 2 Erkrankungen geworfen, die sich an der Schnittstelle befinden: Arthropathie bei Hämochromatose und Systemische Sklerose bei Primär Biliärer Cholangitis. Daneben werden hepatologische Fragestellungen bei rheumatologischer Therapie beleuchtet.

Abstract

Rheumatology and hepatology overlap in a number of conditions that are relevant for physicians in both fields. This review highlights 2 disorders at the interface: arthropathy in haemochromatosis and systemic sclerosis in primary biliary cholangitis. Furthermore, hepatological effects of rheumatological therapies are illuminated.

Schlüsselwörter

Hämochromatose - Systemische Sklerose - Hepatotoxizität - Zirrhose - Primär Biliäre Cholangitis

Key words

haemochromatosis - systemic sclerosis - primary biliary cholangitis - cirrhosis - drug-induced liver injury

• Literatur

• 1 European Association for the Study of the Liver. EASL Clinical Practice Guidelines for HFE Hemochromatosis. J Hepatol 2010; 53: 3-22
• 2 Dymock IW, Hamilton EB, Laws JW. et al. Arthropathy of haemochromatosis. Clinical and radiological analysis of 63 patients with iron overload. Ann Rheum Dis 1970; 29: 469-476
• 3 Schumacher HR. Hemochromatosis and Arthritis. Arthritis Rheum 1964; 7: 41-50
• 4 Sandhu K, Flintoff K, Chatfield MD. et al. Phenotypic analysis of hemochromatosis subtypes reveals variations in severity of iron overload and clinical disease. Blood 2018; 132: 101-110
• 5 Hamilton EB, Bomford AB, Laws JW. et al. The natural history of arthritis in idiopathic haemochromatosis: progression of the clinical and radiological features over ten years. Q J Med 1981; 50: 321-329
• 6 Budiman-Mak E, Weitzner R, Lertratanakul Y. Arthropathy of hemochromatosis. Arthritis Rheum 1977; 20: 1430-1432
• 7 Dallos T, Sahinbegovic E, Aigner E. et al. Validation of a radiographic scoring system for haemochromatosis arthropathy. Ann Rheum Dis 2010; 69: 2145-2151
• 8 Kowdley KV, Belt P, Wilson LA. et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012; 55: 77-85
• 9 Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases.
• 10 Farpour F, Phan SJ, Burns J. et al. Enhanced MR imaging of the shoulder, and sternoclavicular and acromioclavicular joint arthritis in primary hemochromatosis. Rheumatol Int 2011; 31: 395-398
• 11 Papakonstantinou O, Mohana-Borges AV, Campell L. et al. Hip arthropathy in a patient with primary hemochromatosis: MR imaging findings with pathologic correlation. Skeletal Radiol 2005; 34: 180-184
• 12 Chin J, Powell LW, Ramm LE. et al. Utility of Serum Biomarker Indices for Staging of Hepatic Fibrosis Before and After Venesection in Patients With Hemochromatosis Caused by Variants in HFE. Clin Gastroenterol Hepatol 2021; 19: 1459-1468
• 13 Legros L, Bardou-Jacquet E, Latournerie M. et al. Non-invasive assessment of liver fibrosis in C282Y homozygous HFE hemochromatosis. Liver Int 2015; 35: 1731-1738
• 14 Bottone EJ. Yersinia enterocolitica: The charisma continues. Clin Microbiol Rev 1997; 10: 257-276
• 15 Guggenbuhl P, Deugnier Y, Boisdet JF. et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 2005; 16: 1809-1814
• 16 Watt FE, James OFW, Jones DEJ. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM 2004; 97: 397-406
• 17 Rigamonti C, Shand LM, Feudjo M. et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006; 55: 388-394
• 18 Chalifoux SL, Konyn PG, Choi G. et al. Extrahepatic Manifestations of Primary Biliary Cholangitis. Gut Liver 2017; 11: 771-780
• 19 Rigamonti C, Bogdanos DP, Mytilinaiou MG. et al. Primary Biliary Cirrhosis Associated with Systemic Sclerosis: Diagnostic and Clinical Challenges. Int J Rheumatol 2011; 976427
• 20 Assassi S, Fritzler MJ, Arnett FC. et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol 2009; 36: 2250-2256
• 21 Strassburg CP, Beckebaum S, Geier A. S2k Leitlinie Autoimmune Lebererkrankungen. Z Gastroenterol 2017; 55: 1135-1226
• 22 Nevens F, Andreone P, Mazzella G. et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med 2016; 375: 631-643
• 23 Corpechot C, Chazouillères O, Rousseau A. et al. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med 2018; 378: 2171-2181
• 24 Honda A, Tanaka A, Kaneko T. et al. Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis. Hepatology 2019; 70: 2035-2046
• 25 Vanhoof J, Landewe S, Van Wijngaerden E. et al. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 2003; 62: 1241-1242
• 26 Lavery EA, Coyle WJ. Herpes simplex virus and the alimentary tract. Curr Gastroenterol Rep 2008; 10: 417-423
• 27 Kourbeti IS, Ziakas PD, Mylonakis E. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis 2014; 58: 1649-1657
• 28 Ollier L, Tieulie N, Sanderson F. et al. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann Intern Med 2009; 150: 430-431
• 29 Dalton HR, Bendall RP, Keane FE. et al. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 2009; 361: 1025
• 30 Lee HL, Bae SH, Jang B. et al. Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy. Gut Liver 2017; 11: 870-877
• 31 Chan HL, Fung S, Seto WK. et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016; 1: 185-195
• 32 Buti M, Gane E, Seto WK. et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016; 1: 196-206
• 33 S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion. Z Gastroenterol 2021; 59: 691-776
• 34 National Institutes of Health: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury Im Internet: www.livertox.nih.gov
• 35 Kremer JM, Kaye GI, Kaye NW. et al. Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving longterm methotrexate therapy. Followup over long treatment intervals and correlation with clinical and laboratory variables. Arthritis Rheum 1995; 38: 1194-1203
• 36 Kremer JM, Furst DE, Weinblatt ME. et al. Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 1996; 23: 459-461
• 37 Wood PR, Caplan L. Drug-Induced Gastrointestinal and Hepatic Disease Associated with Biologics and Nonbiologic Disease-Modifying Antirheumatic Drugs. Rheum Dis Clin North Am 2018; 44: 29-43
• 38 Kalb RE, Strober B, Weinstein G. et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-837
• 39 Pfizer. Fachinformation Lantarel^® FS 7,5/10/15/20/25 mg Injektionslösung in einer Fertigspritze (Mai 2021). Im Internet: www.fachinfo.de/api/fachinfo/pdf/016008
• 40 Roenigk HH, Auerbach R, Maibach HI. et al. Methotrexate guidelines: revised. J Am Acad Dermatol 1982; 6: 145-155
• 41 Lee SW, Park HJ, Kim BK. et al. Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. Arthritis Res Ther 2012; 14: R232
• 42 Sanofi. Fachinformation Arava^® 10 mg/20 mg/100 mg Filmtabletten (April 2018). Im Internet: www.fachinfo.de/api/fachinfo/pdf/000076
• 43 Craig E, Capelli LC. Gastrointestinal and Hepatic Disease in Rheumatoid Arthritis. Rheum Dis Clin North Am 2018; 44: 89-111
• 44 Sanofi. Fachinformation Quensyl^® (Februar 2021). Im Internet: www.fachinfo.de/api/fachinfo/pdf/00493
• 45 Pfizer. Fachinformation Azulfidine^® (Mai 2021). Im Internet: www.fachinfo.de/api/fachinfo/pdf/004707
• 46 DR. FALK PHARMA GmbH. Fachinformation Azafalk^® (Juni 2021). Im Internet: www.fachinfo.de/api/fachinfo/pdf/013766
• 47 Pfizer. Fachinformation Xeljanz^® 5mg/10mg Filmtabletten (August 2021). Im Internet: www.fachinfo.de/api/fachinfo/pdf/016033
• 48 Lilly. Fachinformation Olumiant^® (Dezember 2020). Im Internet: www.fachinfo.de/api/fachinfo/pdf/021493
• 49 AbbVie. Fachinformation RINVOQ^® (August 2021). Im Internet: www.fachinfo.de/api/fachinfo/pdf/022727
• 50 Gilead. Fachinformation Jyseleca^® (April 2021). Im Internet: www.fachinfo.de/api/fachinfo/pdf/023126
• 51 Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008; 38: 208-217
• 52 Li S, Kaur PP, Chan V. et al. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol 2009; 28: 787-791
• 53 Roche. Fachinformation RoActemra^® Fertigpen (Mai 2021). Im Internet: www.fachinfo.de/api/fachinfo/pdf/021999
• 54 Sanofi Genzyme. Fachinformation Kevzara^® (November 2020). Im Internet: https://www.fachinfo.de/api/fachinfo/pdf/021587
• 55 Lin KM, Lin JC, Tseng WY. et al. Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis. J Microbiol Immunol Infect 2013; 46: 65-67